Drug Profile
LX 9211
Alternative Names: LX-9211Latest Information Update: 06 Dec 2023
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb; Lexicon Pharmaceuticals
- Developer Lexicon Pharmaceuticals
- Class Analgesics; Small molecules
- Mechanism of Action Adaptor-associated kinase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Neuropathic pain; Postherpetic neuralgia
Most Recent Events
- 29 Nov 2023 Lexicon initiates enrolment in the phase IIb PROGRESS trial for Neuropathic pain in USA (PO, Tablet) (NCT06203002)
- 08 Nov 2023 Lexicon Pharmaceuticals anticipates first patient enrollment in a phase IIb trial for Neuropathic pain in early December 2023
- 02 Oct 2023 Safety and efficacy data from a phase II trial in Neuropathic pain presented at the trial at the 59th Annual Meeting of the European Association for the Study of Diabetes (EASD-2023)